International clinical trial finds semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity who do not have diabetes
Cleveland, November. Findings from an international multicentre clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who…
See more International clinical trial finds semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity who do not have diabetes